全文获取类型
收费全文 | 20216篇 |
免费 | 1709篇 |
国内免费 | 554篇 |
专业分类
耳鼻咽喉 | 174篇 |
儿科学 | 330篇 |
妇产科学 | 577篇 |
基础医学 | 2588篇 |
口腔科学 | 429篇 |
临床医学 | 2213篇 |
内科学 | 4165篇 |
皮肤病学 | 251篇 |
神经病学 | 1244篇 |
特种医学 | 496篇 |
外国民族医学 | 3篇 |
外科学 | 2971篇 |
综合类 | 1481篇 |
现状与发展 | 3篇 |
一般理论 | 5篇 |
预防医学 | 1117篇 |
眼科学 | 746篇 |
药学 | 1631篇 |
6篇 | |
中国医学 | 568篇 |
肿瘤学 | 1481篇 |
出版年
2023年 | 212篇 |
2022年 | 219篇 |
2021年 | 614篇 |
2020年 | 463篇 |
2019年 | 506篇 |
2018年 | 602篇 |
2017年 | 529篇 |
2016年 | 521篇 |
2015年 | 688篇 |
2014年 | 862篇 |
2013年 | 979篇 |
2012年 | 1489篇 |
2011年 | 1581篇 |
2010年 | 932篇 |
2009年 | 761篇 |
2008年 | 1150篇 |
2007年 | 1169篇 |
2006年 | 1199篇 |
2005年 | 1200篇 |
2004年 | 966篇 |
2003年 | 855篇 |
2002年 | 820篇 |
2001年 | 549篇 |
2000年 | 537篇 |
1999年 | 488篇 |
1998年 | 189篇 |
1997年 | 190篇 |
1996年 | 154篇 |
1995年 | 122篇 |
1994年 | 120篇 |
1993年 | 92篇 |
1992年 | 231篇 |
1991年 | 201篇 |
1990年 | 176篇 |
1989年 | 157篇 |
1988年 | 124篇 |
1987年 | 124篇 |
1986年 | 101篇 |
1985年 | 76篇 |
1984年 | 57篇 |
1983年 | 46篇 |
1982年 | 51篇 |
1981年 | 47篇 |
1980年 | 40篇 |
1979年 | 41篇 |
1978年 | 39篇 |
1977年 | 21篇 |
1975年 | 24篇 |
1974年 | 21篇 |
1971年 | 17篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Dongbing Lai Emma C. Johnson Sarah Colbert Gayathri Pandey Grace Chan Lance Bauer Meredith W. Francis Victor Hesselbrock Chella Kamarajan John Kramer Weipeng Kuang Sally Kuo Samuel Kuperman Yunlong Liu Vivia McCutcheon Zhiping Pang Martin H. Plawecki Marc Schuckit Jay Tischfield Leah Wetherill Yong Zang Howard J. Edenberg Bernice Porjesz Arpana Agrawal Tatiana Foroud 《Alcoholism, clinical and experimental research》2022,46(3):374-383
2.
3.
Amandeep R. Mahal Laura D. Cramer Elyn H. Wang Shiyi Wang Amy J. Davidoff Cary P. Gross James B. Yu 《Journal of Geriatric Oncology》2021,12(1):102-105
ObjectivesAlthough survival after a cancer diagnosis has improved considerably over the past 20 years, little is known about trends in health-related quality-of-life (HRQOL) for older prostate, breast, and lung cancer survivors.MethodsUsing a population-based registry with longitudinal patient reported outcomes (the National Cancer Institute Surveillance, Epidemiology and End Results database linked to Medicare Health Outcomes Survey), we analyzed Medicare Advantage patients diagnosed with cancer during 1998–2011, who completed surveys regarding HRQOL through 2013. ‘Early Era’ patients were treated during 1998–2003; ‘Late Era’ patients were treated during 2006–2011. After propensity score matching, post-diagnosis changes in health utility (HU), Physical Component Summary (PCS) and Mental Component Summary (MCS) scores were calculated and compared between the two eras.ResultWe identified 208 older patients with prostate, 276 with breast and 76 with lung cancer who were treated in the ‘Early Era’ and matched to equal numbers in the ‘Late Era’. Mean age of patients in early and late era was 72 and 73 years, respectively. The mean post-diagnosis decline in health utility for patients treated in the ‘Late Era’ was not significantly different from the ‘Early Era’ for any cancer (Prostate [early vs. late]: ?0.06 vs. -0.03, p = .09; Breast: ?0.03 vs. ?0.04, p = .65; Lung: ?0.07 vs. ?0.07, p = .95); nor for Physical Component Summary or Mental Component Summary scores.ConclusionOlder patients treated for prostate, breast or lung cancer in the later era reported similar outcomes of changes in HRQOL compared to earlier era patients. 相似文献
4.
Stephanie H. Ameis John D. Haltigan Rachael E. Lyon Amanda Sawyer Pat Mirenda Connor M. Kerns Isabel M. Smith Tracy Vaillancourt Joanne Volden Charlotte Waddell Lonnie Zwaigenbaum Teresa Bennett Eric Duku Mayada Elsabbagh Stelios Georgiades Wendy J. Ungar Anat Zaidman-Zait Meng-Chuan Lai Peter Szatmari for the Pathways in ASD Study Team 《Journal of child psychology and psychiatry, and allied disciplines》2022,63(5):553-562
5.
6.
7.
8.
Cho Nicholas Wang Chencai Raymond Catalina Kaprealian Tania Ji Matthew Salamon Noriko Pope Whitney B. Nghiemphu Phioanh L. Lai Albert Cloughesy Timothy F. Ellingson Benjamin M. 《Journal of neuro-oncology》2020,147(3):643-652
Journal of Neuro-Oncology - There is growing evidence that the subventricular zone (SVZ) plays a key role in glioblastoma (GBM) tumorigenesis. However, little is known regarding how the SVZ, which... 相似文献
9.
Wei-Fan Hsu Po-Heng Chuang Cheng-Kuo Chen Hung-Wei Wang Ming-Hung Tsai Wen-Pang Su Hung-Yao Chen Chi-Ying Yang Chun-Che Lin Guan-Tarn Huang Jaw-Town Lin Hsueh-Chou Lai Cheng-Yuan Peng 《American journal of cancer research》2020,10(12):4547
Real-world predictors of the treatment efficacy of immune checkpoint inhibitors for hepatocellular carcinoma (HCC) are unknown. This retrospective study enrolled 87 consecutive patients with unresectable HCC from May 2017 to December 2019 at two hospitals. Of the 87 patients, 7, 9, 60, and 11 patients had Barcelona Clinic Liver Cancer stages A, B, C, and D, respectively, and 45, 30, and 10 patients were Child-Pugh class A, B, and C, respectively. The median injection numbers of nivolumab and treatment duration were 6 (3-8) and 2.53 (1.47-4.23) months, respectively, and 64.4% of patients received combination therapy. Radiological imaging was not assessed for 25 patients. Objective response (OR) and disease control rates were 19.5% and 39.1%, respectively. A single tumor (odds ratio: 9.542, P = .015) and ≥20% decline in serum α-fetoprotein protein (AFP) levels within the first 3 months of treatment (defined as AFP response, odds ratio: 5.997, P = .042) were predictors of OR. Lack of macrovascular invasion, combination therapy, and AFP response were predictors of progression-free survival. A Cancer of the Liver Italian Program (CLIP) score of 0-2 (hazard ratio [HR]: 3.717, P = .004) and grade 1-2 immune-related adverse events (irAEs, HR: 2.217, P = .049) were predictors of overall survival (OS) in the entire cohort, and a CLIP score of 0-2 (HR: 3.257, P = .009) was a predictor of OS in evaluable patients. IrAEs ≥ grade 3 were noted in 14 patients, and three died as a result. Having a single tumor and AFP response were predictors of OR, and CLIP score was a predictor of OS. 相似文献